BACKGROUND: High-intensity care including hospitalizations, chemotherapy, and other interventions at the end of life is costly and often of little value for cancer patients. Little is known about patterns of end-oflife care and resource utilization for women with uterine cancer. OBJECTIVE: We examined the costs and predictors of aggressive endof-life care for women with uterine cancer. STUDY DESIGN: In this observational cohort study the Surveillance, Epidemiology, and End Results-Medicare linked database was used to identify women age 65 years who died from uterine cancer from 2000 through 2011. Resource utilization in the last month of life including 2 hospital admissions, >1 emergency department visit, 1 intensive care unit admission, or use of chemotherapy in the last 14 days of life was examined. High-intensity care was defined as the occurrence of any of the above outcomes. Logistic regression models were developed to identify factors associated with high-intensity care. Total Medicare expenditures in the last month of life are reported. RESULTS: Of the 5873 patients identified, the majority had stage IV cancer (30.2%), were white (79.9%), and had endometrioid tumors (47.6%). High-intensity care was rendered to 42.5% of women. During the last month of life, 15.0% had 2 hospital admissions, 9.0% had a hospitalization >14 days, 15.3% had >1 emergency department visits, 18.3% had an intensive care unit admission, and 6.6% received chemotherapy in the last 14 days of life. The percentage of women who received high-intensity care was stable over the study period. Characteristics of younger age, black race, higher number of comorbidities, stage IV disease, residence in the eastern United States, and more recent diagnosis were associated with highintensity care. The median Medicare payment during the last month of life was $7645. Total per beneficiary Medicare payments remained stable from $9656 (interquartile range $3190-15,890) in 2000 to $9208 (interquartile range $3309-18,554) by 2011. The median health care expenditure was 4 times as high for those who received high-intensity care compared to those who did not (median $16,173 vs $4099). CONCLUSION: Among women with uterine cancer, high-intensity care is common in the last month of life, associated with substantial monetary expenditures, and does not appear to be decreasing.
Introduction
Patients with advanced cancer often receive expensive, aggressive medical treatment including chemotherapy and intensive inpatient care when it is of questionable clinical value and has the potential to worsen quality of life. [1] [2] [3] [4] [5] A review of claims in the last 30 days of life for cancer patients found that 52% of them had an acute care hospitalization, 27% an intensive care unit admission, 46% visited the emergency department, and 11% were given intravenous chemotherapy. 1 Health care spending at the end of life among patients with cancer diagnoses far exceeds that of those without cancer. 2 Even among patients with cancer, those who die "from cancer" have higher health care expenditures at the end of life than those who die from causes of death other than cancer. 3 Endof-life discussions have been associated with lower cost at the end of life. Zhang et al 4 found 35% lower end-of-life costs among patients who reported having end-of-life discussion compared to those who did not. Similarly, those with documented do-not-resuscitate orders also incur lower costs and report better quality of life compared to those who lack them. 5 Estimates of health care spending during the end of life for women with ovarian cancer show that inpatient care and chemotherapy account for a large portion of cost and that these costs are lower in those who elect to receive hospice care. 6 Few data exist for health care costs at the end of life for gynecologic cancers other than ovarian cancer. Up to 24% of patients with a gynecologic malignancy including ovarian, uterine, cervical, vaginal, or vulvar cancer were reported to receive aggressive medical care in the last 30 days of life including chemotherapy, hospital admission, and intensive care unit admission. 7 Patients who experience more intensive medical care at the end of life are more likely to report poorer quality of life. 8 Limited data on the financial burden of end-of-life care are currently available for patients with uterine cancer. Identifying the patterns of care and resultant financial burden of patients with uterine cancer at the end of life is important. Allocating interest and resources to improve end-of-life care for patients with a gynecologic malignancy that is usually associated with a favorable prognosis requires defining the scope of the issue. The objective of our study was to quantify end-of-life health care spending among women with uterine cancer and identify associations with high-intensity care and increased health care spending. 
Materials and Methods
We used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database for analysis. We identified women >65 years of age who had uterine cancer diagnosed as their first or only cancer and confirmed with positive histology. We included women whose cause of death was uterine cancer from 2000 through 2011, and who had a valid date of death with agreement between SEER and Medicare within the month of death. We excluded women diagnosed by autopsy or death certificate, or who were eligible for Medicare because of end-stage renal disease or disability. We also excluded women who did not have full coverage for both Medicare parts A and B or who were enrolled in a nonMedicare health maintenance organization from 12 months prior to death through time of death because of incomplete billing claims submitted to Medicare for reimbursement.
The clinical and demographic characteristics included year of diagnosis (1998 through 2011), year of death (2000 through 2011), age at diagnosis (65-69, 70-74, 75-79, 80 years), race (white, black, Hispanic, other/unknown), marital status (married, unmarried, unknown), location (metropolitan, nonmetropolitan, unknown), and region of SEER registry (East, Midwest, West). An aggregate socioeconomic status score was derived from census tract data on education, poverty level, and income, as previously reported by Du and colleagues. 9 The formula weighted education, poverty, and income equally and ranked patients on a scale of 1-5 with 1 being the lowest value. We used the Klabunde et al 10 adaptation of the Charlson et al 11 comorbidity index to assess the presence of comorbid medical conditions, and grouped patients as 0, 1, or 2 comorbid conditions. Tumor histology was classified as endometrioid, serous, clear cell, carcinosarcoma, leiomyosarcoma, and other. Tumor grade was grouped as 1, 2, 3, and other/unknown. Stage was captured using American Joint Committee on Cancer criteria and grouped as I, II, III, IV, and unknown. Patients with early-stage disease ultimately died of uterine cancer, as this was necessary for inclusion in the study. These patients were assumed to eventually have presented with recurrent advanced disease and therefore were an important population to include. ajog.org
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We examined utilization of hospital admissions including those with length of stay >14 days, emergency department visits, intensive care unit admissions, administration of chemotherapy, and hospice services at the end of life in accordance with previously published indicators of aggressive medical care at the end of life. 12 Hospitalization, emergency department visitation, and intensive care unit admissions were analyzed during the last month of life. Hospice admission was categorized based on the first occurrence and analyzed as occurring in the last 3 days, and 1, 3, and 6 months of life. Use of intravenous chemotherapy in the last 14 days of life was also examined.
Data on emergency department visits were extracted by searching the source and type codes of inpatient admission, the Healthcare Common Procedure Coding System, Berenson-Eggers Type of Service for procedure codes and revenue center codes from Medicare Provider Analysis and Review (MEDPAR), carrier claims, and outpatient claims. One MEDPAR admission that had emergency department indicators in the last month of life was considered 1 emergency department visit. For emergency department visits identified from carrier and outpatient claims in the last month of life, claims occurred on the same day were considered 1 emergency department visit. [12] [13] [14] Intensive care unit admission was defined as the presence of an intensive care unit indicator code; intensive care day count >0; or International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes for continuous invasive mechanical ventilation (96.7x) from MEDPAR within the last month of life as previously described. 13, 15, 16 Data on use of intravenous chemotherapy were extracted by searching the Healthcare Common Procedure Coding System; International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis and procedure codes; and revenue center codes from MEDPAR, carrier, and outpatient claims. If a patient had at least 1 claim for chemotherapy within the last 14 days of life, she was coded as having received chemotherapy.
We developed a classification schema to identify high utilization of medical services at the end of life. High-intensity care was defined as utilization of 2 hospital admissions, or 1 hospital admissions with length of stay >14 days, or >1 emergency department visit or 1 intensive care unit admission in the last month of life or use of intravenous chemotherapy in the last 14 days, or first hospice admission in the last 3 days of life. We also examined total Medicare expenditures in the last month of life. Medicare expenditures were estimated by summing all payments from MEDPAR, carrier and outpatient claims, durable medical equipment, and hospice in the last month of life. The total cost was adjusted for inflation to 2015 dollars and winsorized to the 3rd and 97th percentiles. 17 Patient demographics were reported descriptively. High-intensity care and the other outcomes were reported as number and percentage of patients who had the services stratified by year of death, and were compared using Cochran-Armitage test for linear trend in proportions. Medicare expenditures in the last month of life were reported as median and interquartile range and compared using Wilcoxon rank sums and KruskalWallis tests. Logistic regression 
Results
We identified 5873 women who died of uterine cancer from 2000 through 2011 (Supplemental Figure) . Demographic descriptors of the cohort are displayed in (Figure, A) .
The median overall health care expenditure during the last month of life was $7645 (interquartile range $3217-16,246) ( Table 3) . Year-by-year median health care expenditures can be found in Figure, B , and the health care spending across the study period was stable (Table 3) . Among those who received high-intensity care, health care expenditures were 4 times higher ($16,173 vs $4099) than for those who did not receive highintensity care (P < .001).
In (Table 4 ). In contrast, fewer older women and residents of the midwestern (compared to eastern) United States received high-intensity care. There was no association between socioeconomic status and receipt of high-intensity care.
Comment
Among women with uterine cancer, aggressive therapy at the end of life is common. Despite increased availability of palliative care services, hospitalization, emergency department visits, and use of chemotherapy in the last month of life remained frequent. Importantly, while we observed some year-to-year variation in the costs of care during the last month of life, overall costs have remained relatively stable over time and have not declined significantly.
Prior studies in women with gynecologic cancers showed that intensive treatment, including hospitalizations and use of chemotherapeutic agents, is common at the end of life. Wu and colleagues 18 reported that 30% of patients with a gynecologic malignancy received a therapeutic intervention (chemotherapy, radiation therapy, or surgery) in Original Research GYNECOLOGY ajog.org the last month of life. Zakhour and colleagues 19 studied the effect of documented end-of-life discussions on health care utilization and reported similar measures of health care utilization during the last 30 days of life (eg, 40% emergency department visit in last 30 days, 49% hospital admission in last 30 days). We observed that 6.6% of patients received chemotherapy during the last 14 days of life, which is similar to 4% reported in a single-institution retrospective review of gynecologic oncology patients and 4.8-12.7% in a multicountry retrospective study of patients with multiple tumor types during the last 30 days of life. 1, 20 Our data from a large cohort of elderly women with uterine cancer revealed similar trends; the use of hospital services and chemotherapy are common at the end of life.
A number of patient, physician, and systems factors likely influence the intensity of care at the end of life for cancer patients. 6 Regional variation appears to be an important factor in the intensity of end-of-life care. Our data suggest highintensity care in the last month of life is more common in the eastern United States compared to the midwestern region, further supporting that practice patterns can have a large influence of health care cost. Race has also been associated with receiving aggressive endof-life care. In a report by Wright and colleagues, black patients with stage IV cancer were 3 times more likely to receive high-intensity care at the end of life. 8 We similarly found that black race was associated with receiving highintensity end-of-life care. Black patients are also less likely to have a documented do-not-resuscitate order or advance directive and be less likely to receive opiates and benzodiazepines while hospitalized compared to white patients.
21, 22 Ramey and Chin 23 demonstrated that black patients with cancer (all sites) use hospice services at a lower rate compared to white patients with cancer, which is in line with our observation of their likelihood to receive highintensity care at the end of life. Possible explanations for this observation include poor access to care, lack of appropriate referral to hospice, cultural beliefs, and preference for aggressive treatments. The higher incidence and mortality of black patients with endometrial cancer makes addressing quality of end-of-life care in this population specifically an important issue that should be prioritized. 24 While we did not find data on end-of-life health care costs among black patents with gynecologic malignancies, black patients with prostate cancer had higher costs during the last year of life compared to non-Hispanic white patients. 25 Health care costs during the last month of life for patients with uterine cancer demonstrated some year-to-year variation, but were relatively stable over the course of our study period. Limited data exist to provide a comparison regarding trends in overall end-of-life costs over time. In line with the cost data that we noted, high-intensity care, hospitalizations, and use of chemotherapy were relatively stable over the course of the study. Despite the recent focus on incorporation of palliative care into routine oncology practice and its intended effect on reducing aggressive care and health care costs at the end of life, these data are not supportive of decreasing costs or high-intensity care. These data are in contrast with a review of cancer decedents from Canada that reported increases in systemic therapy cost and use during the last year of life from 2002 through 2007. 26 It is possible that we are observing a lag time between the dissemination of guidelines promoting routine incorporation of palliative care into oncology care for patients with advanced cancer and widespread incorporation of these recommendations into clinical practice that would produce a measurable effect.
The immense financial burden of cancer care on the US health care system, especially at the end of life, has sparked interest in how to improve patient care while reducing cost. Transitioning to They also showed less hospice use among women who were black, lower income, and using Medicare fee for service. A separate study of ovarian cancer patients showed a more modest increase in hospice discharges from an inpatient unit from 2006 through 2011 of 9.2-11.1%. 27 Similar trends have been noted for other disease sites. 29, 30 While this work represents one of the first studies to examine end-of-life care in women with uterine cancer, we recognize a number of important limitations. First, our data represent reimbursements and may not capture the true cost of care. While Medicare claims data likely do not represent the entirety of health care costs at the end of life, these data have been widely used as a surrogate for medical spending. Second, as with any study of claims data, there may be the undercapture of some services as well as use of hospice care. However, we examined only major interventions likely to generate a billing code and this data set has been used in a number of other studies to examine hospice services. Third, our data derive from a cohort of women age 65 years due to the nature of the database we used and therefore our results might not be applicable to a population of women age <65 years. Fourth, by selecting only those with documented cause of death as gynecologic malignancy we significantly reduced our sample size. This was done to avoid including patients who died of other causes but ultimately is subject to variations in reporting. For example, someone who dies of extensive thromboembolic disease secondary to their hypercoagulable state caused by metastatic endometrial cancer would not be captured in this study if their cause of death was not listed as gynecologic malignancy. Finally, due to the retrospective nature of the study, associations identified cannot be assumed to be causal. As with any observational study, we cannot assess individual patient and physician attitudes and beliefs that undoubtedly influenced decision-making and ultimately resource utilization and cost. While care at the end of life should be individualized, treatment goals for women with advanced uterine cancer should focus on preserving quality of life and palliation of symptoms. Ideally, such care would result in avoidance of procedures and systemic therapies, and minimization of hospitalization and emergency room visits. Our data show that this ideal is not the reality for many patients who die of uterine cancer. Further efforts should be made to improve the transition away from intensive medical care to end-of-life care. n Year of diagnosis 1998-2011-6,040
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